上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。
PD180970
PD180970 是一种高效且具有 ATP 竞争性的 p210Bcr-Abl 激酶抑制剂，可抑制 p210Bcr-Abl 的自磷酸化，IC50 为 5 nM。PD180970 还抑制 Src 和 KIT 激酶，IC50 分别为 0.8 nM 和 50 nM。PD180970 可诱导 K562 白血病细胞凋亡 (apoptosis)，可用于慢性粒细胞白血病的研究。
PD180970 Chemical Structure
CAS No. : 287204-45-9
| 规格 |
|
是否有货 |
|
| 100 mg |
|
询价 |
|
| 250 mg |
|
询价 |
|
| 500 mg |
|
询价 |
|
* Please select Quantity before adding items.
| 生物活性 |
PD180970 is a highly potent and ATP-competitive p210Bcr-Abl kinase inhibitor, with an IC50 of 5 nM for inhibiting the autophosphorylation of p210Bcr-Abl. PD180970 also inhibits Src and KIT kinase with IC50s of 0.8 nM and 50 nM, respectively. PD180970 indcues apoptosis of K562 leukemic cells, and can be used for chronic myelogenous leukemia research[1][2][3].
|
| IC50 & Target[1][2] |
|
Bcr-Abl
5 nM (IC50, p210Bcr-Abl kinase)
|
Src
0.8 nM (IC50)
|
KIT
50 nM (IC50)
|
|
体外研究
(In Vitro) |
PD180970 (0.5 μM; 24-96 hours) treatment causes cell death K562 cells[1].
PD180970 (0.5 μM; 24-48 hours) treatment induces apoptosis of K562 cells. The result shows increase in annexin V-PI double-positive cells[1].
PD180970 inhibits tyrosine phosphorylation of p210Bcr-Abl, Gab2, and CrkL in K562 cells with IC50 values of 170 nM, 80 nM, and 80 nM, respectively. In vitro, PD180970 potently inhibits autophosphorylation of p210Bcr-Abl (IC50 of 5 nM) and the kinase activity of purified recombinant Abl tyrosine kinase (IC50 of 2.2 nM)[1].
The blocking Bcr-Abl kinase activity using PD180970 in the human K562 CML cell line resulted in inhibition of Stat5 DNA-binding activity with an IC50 of 5 nM[2].
Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Viability Assay[1]
| Cell Line: |
K562 cells |
| Concentration: |
0.5 μM |
| Incubation Time: |
24 hours, 48 hours, 72 hours, 96 hours |
| Result: |
Resulted in cell death. |
Apoptosis Analysis[1]
| Cell Line: |
K562 cells |
| Concentration: |
0.5 μM |
| Incubation Time: |
24 hours, 48 hours |
| Result: |
Increased annexin V-positive/PI-negative cells. |
|
体内研究
(In Vivo) |
PD180970 (5 mg/kg; intraperitonial injection; daily; for 7 days) mitigates MPTP-induced neuronal loss in mice. PD180970 has the neuroprotective ability in a preclinical mouse model of Parkinson’s disease (PD)[4].
Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: |
Male C57BL/6J mice (3-4 months old) injected with MPTP[4] |
| Dosage: |
5 mg/kg |
| Administration: |
Intraperitonial injection; daily; for 7 days |
| Result: |
Decreased number of activated microglia on activation by MPTP in mice brains. And showed significant reduction in intensity of Iba1 expression in activated microglia. |
|
| 分子量 |
|
| Formula |
|
| CAS 号 |
|
| 运输条件 |
Room temperature in continental US; may vary elsewhere.
|
| 储存方式 |
Please store the product under the recommended conditions in the Certificate of Analysis.
|
| 参考文献 |
-
[1]. J F Dorsey, et al. The pyrido[2,3-d]pyrimidine derivative PD180970 inhibits p210Bcr-Abl tyrosine kinase and induces apoptosis of K562 leukemic cells. Cancer Res. 2000 Jun 15;60(12):3127-31.
[2]. Mei Huang, et al. Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells. Oncogene. 2002 Dec 12;21(57):8804-16.
[3]. Amie S Corbin, et al. Sensitivity of oncogenic KIT mutants to the kinase inhibitors MLN518 and PD180970. Blood. 2004 Dec 1;104(12):3754-7.
[4]. Suresh Sn, et al. Small molecule modulator of aggrephagy regulates neuroinflammation to curb pathogenesis of neurodegeneration. EBioMedicine. 2019 Dec;50:260-273.
|
所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务
